Dexcom, Inc. (NASDAQ:DXCM) has appointed Renée Galá to its board of directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic, and operational leadership experience across the life sciences sector. She currently serves as the President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than $4 billion in total revenues in 2024.
Ms. Galá brings to the Dexcom board a strong track record of strategic and financial leadership at high-growth companies, including oversight of key international expansion initiatives and business development collaborations.
In her previous roles, Ms. Galá served as the Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals from 2020 to 2023 and held various finance roles at Theravance Biopharma, Inc. and Eli Lilly and Company.
Dexcom, Inc., founded in 1999, has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
As of the latest financial reporting period, Dexcom, Inc.'s total revenues were [INSERT FIGURE], representing a [INSERT PERCENTAGE CHANGE] increase from the previous period. Additionally, the company's operating income stood at [INSERT FIGURE], reflecting a [INSERT PERCENTAGE CHANGE] change from the last reporting period. Moreover, Dexcom, Inc.'s net income for the period was [INSERT FIGURE], indicating a [INSERT PERCENTAGE CHANGE] shift from the previous period.
Ms. Galá's appointment to the board comes at a key point in Dexcom's journey, as the company aims to empower greater metabolic health for millions of people around the world. Kevin Sayer, Chairman, President, and CEO at Dexcom, expressed excitement about Ms. Galá's appointment, citing her extensive experience in guiding global finance and operations as a valuable addition to the board. As a result of these announcements, the company's shares have moved -8.2% on the market, and are now trading at a price of $71.44. For the full picture, make sure to review DexCom's 8-K report.
